Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07703683

Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases

Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.

.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diabetes Adrenal Gland Diseases Adrenocortical Hyperfunction Atrophy Body Weight Cushing Syndrome Diabetes Mellitus Endocrine Diseases Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity & Overweight Overnutrition Overweight Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Sarcopenia Sarcopenic Obesity Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cliniques Universitaires Saint-Luc

Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, 1150, Belgium

Location status: Recruiting

Location contact

Laura Orioli, MD, PhD

CONTACT

[email protected]

+32494507621

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Metabolic or endocrine disease

Exclusion criteria

  • Known myopathy
  • Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
  • Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
  • History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor

Treatment and study plan

GLP-1 Receptor Agonists

Drug

Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity

Other names: GLP-1/GIP dual agonists

Primary outcomes

  1. Prevalence of sarcopenia / sarcopenic obesity

    Time frame: From February 2026 to december 2056

Secondary outcomes

  1. Myokines levels in serum or plasma

    Time frame: February 2026 to December 2056

    Myokines levels in serum or plasma as measured by ELISA

  2. Myokine expression

    Time frame: February 2026 to December 2056

    Myokine expression in muscle as measured by RT-qPCR or RNA-Seq

  3. Prevalence of MASLD

    Time frame: March 2026 to December 2056

    MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis

  4. Prevalence of MASH

    Time frame: March 2026 to December 2056

    Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis

Study contacts

Contact information is provided by the study sponsor or research team.

Laura Orioli, MD, PhD

CONTACT

[email protected]

+32494507621

Sponsors and collaborators

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Other

Registry information

Acronym: SARC-ENDO

Important dates

Study start
2026
Primary completion
2056
Study completion
2056
First posted
Jul 14, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.